000 | 02003 a2200601 4500 | ||
---|---|---|---|
005 | 20250514190427.0 | ||
264 | 0 | _c20040712 | |
008 | 200407s 0 0 eng d | ||
022 | _a1424-9634 | ||
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aLiénard, Danielle | |
245 | 0 | 0 |
_aEx vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. _h[electronic resource] |
260 |
_bCancer immunity _cMay 2004 |
||
300 |
_a4 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAdolescent |
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAged |
650 | 0 | 4 | _aAntigens, Neoplasm |
650 | 0 | 4 |
_aCD8-Positive T-Lymphocytes _ximmunology |
650 | 0 | 4 |
_aCancer Vaccines _ximmunology |
650 | 0 | 4 |
_aDermatitis _xetiology |
650 | 0 | 4 | _aDisease Progression |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 |
_aFreund's Adjuvant _xtherapeutic use |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aLipids _xtherapeutic use |
650 | 0 | 4 | _aLymphocyte Activation |
650 | 0 | 4 | _aMART-1 Antigen |
650 | 0 | 4 | _aMale |
650 | 0 | 4 |
_aMelanoma _xdiagnosis |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aMonitoring, Immunologic |
650 | 0 | 4 |
_aNeoplasm Proteins _ximmunology |
650 | 0 | 4 |
_aPeptides _ximmunology |
650 | 0 | 4 |
_aViral Matrix Proteins _ximmunology |
700 | 1 | _aRimoldi, Donata | |
700 | 1 | _aMarchand, Marie | |
700 | 1 | _aDietrich, Pierre-Yves | |
700 | 1 | _avan Baren, Nicolas | |
700 | 1 | _aGeldhof, Christine | |
700 | 1 | _aBatard, Pascal | |
700 | 1 | _aGuillaume, Philippe | |
700 | 1 | _aAyyoub, Maha | |
700 | 1 | _aPittet, Mikaël J | |
700 | 1 | _aZippelius, Alfred | |
700 | 1 | _aFleischhauer, Katharina | |
700 | 1 | _aLejeune, Ferdy | |
700 | 1 | _aCerottini, Jean-Charles | |
700 | 1 | _aRomero, Pedro | |
700 | 1 | _aSpeiser, Daniel E | |
773 | 0 |
_tCancer immunity _gvol. 4 _gp. 4 |
|
999 |
_c14858025 _d14858025 |